Pradaxa is a blood-thinning drug typically prescribed to patients with atrial fibrillation to prevent blood clots. It was approved in October 2010 by the FDA for the prevention of stroke in patients with non-valvular atrial fibrillation, and was the first alternative to warfarin (Coumadin) approved in nearly 60 years. The U.S. Food and Drug Administration has already received over 500 reports of Pradaxa-related deaths. Reported complications include over 900 reports of gastrointestinal hemorrhages, over 300 reports of rectal hemorrhages, and over 200 reports of cerebrovascular accidents. The FDA is now conducting a safety review of the drug, which millions of people around the country take twice a day.
If you or a loved one suffered serious complications from taking Pradaxa, call (312) 828-9666 or e-mail Pfaff & Gill, Ltd. today. (Contact Us)
In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigations, MDL No. 2385.